Depending on the regulatory jurisdiction, Nanobiotix’s radiation-activated cancer nanotechnology may be a drug or a device. But regardless of classification, it offers a physical solution to problems that chemistry and biology cannot solve.

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.

Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.